Navigation Links
Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Date:1/7/2014

HOUSTON, Jan. 7, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced today that it has completed a second and final closing of its Series B financing, securing an additional $14.7 million and bringing the total raised in the round to $34.4 million. Current investors provided the additional funding, including AVG Ventures and Remeditex Ventures.

The funding will be used to expand clinical development of Bellicum's lead cellular immunotherapy product candidates.

"Bellicum is well positioned within the highly promising field of cellular immunotherapy with a technology that provides control over cells after they have been administered to the patient," said Bellicum CEO Tom Farrell. "This funding will be used to advance our two clinical programs in leukemia/lymphoma and prostate cancer, and launch studies in additional indications where there is urgent need for safer and more effective cell therapies."

Bellicum's two lead clinical development programs utilize the Company's unique ability to control cell therapies once inside the body. BPX-501 T cells contain the Company's CaspaCIDe™ gene "safety switch," enabling physicians to eliminate transplanted cells in the event they become harmful to the patient. The product is being evaluated in a Phase I/II study to reduce or eliminate Graft versus Host Disease in cancer patients undergoing hematopoietic stem cell transplant.

BPX-201 dendritic cells contain the Company's DeCIDe® gene "on switch," which enables physicians to strategically target immune activation for a more potent anti-tumor effect. It is being evaluated in a Phase I clinical trial in patients with metastatic castrate-resistant prostate cancer.

About Bellicum Pharmaceuticals

Bellicum is dedicated to developing safer and more effective cell therapies to treat cancers and other serious, life-threatening diseases. The Company's cell therapies are engineered with a gene "switch" that enables physicians to activate or eliminate cells once inside the body to improve safety and efficacy. Bellicum is advancing clinical programs in cellular transplants to reduce or eliminate Graft versus Host Disease, and in prostate cancer with a potentially more potent immunotherapy. For more information please visit www.bellicum.com


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
2. Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
3. ANI Pharmaceuticals Enters Development Agreement for Generic Drug Product with Sterling Pharmaceutical Services
4. Arena Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
5. Isis Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
6. Inovio Pharmaceuticals to Present at Biotech Showcase 2014 Investor Conference
7. Global Radiopharmaceuticals Market Report 2013 - 2018
8. Pre-Market Update: MGT Capital Investments, National American University Holdings and Actinium Pharmaceuticals
9. ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
10. New Appointments, and Share Price Movements - Research Report on Humana, Illumina, Edwards Lifesciences, Aegerion Pharmaceuticals, and CytRx
11. Taiwan Spends a High Percentage of its Healthcare Budget on Pharmaceuticals, but Second Generation Healthcare Reform is Transforming the Market Landscape
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... -- May is Stroke Awareness Month and Omron Healthcare is ... to prevent a stroke: monitor and manage your blood ... Prevention, undetected and uncontrolled hypertension is a leading risk ... in personal heart health technology, recently evolved its mission ... stroke and is advancing a national public education effort ...
(Date:5/4/2017)... , May 4, 2017 Clarius ... its wireless, handheld ultrasound scanners this week at ... Scientific Meeting (ACOG) in San Diego, ... "Clarius is the perfect tool for ... and heart rate, and evaluate pregnancy-related complications like ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas Rallis ... have now spent 10 years as clinical instructors for the reputable Full Mouth ... Dentistry. Through the program, private practitioners receive cutting-edge clinical training and learn how ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... completed Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. ... the latest advancements in his field by attending numerous CE courses each year. ...
(Date:5/24/2017)... Park, NY (PRWEB) , ... May 24, 2017 ... ... announced the practice is offering holistic pediatric dentistry options for its patients on ... context of the patient’s entire physical well being, and is one of the ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... fluoride (PVDF) based sleep diagnostics sensors, announced today it had completed the first ... of a mix of domestic and rest of world (ROW) authorized dealers specializing ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Carolina have remained steady since 2009, according to a Workers Compensation Research Institute ... study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition looks ...
Breaking Medicine News(10 mins):